The HSE Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The final decision on reimbursement is made by the HSE Senior Management.
The HSE Drugs Group comprises of 15 members, including three public interest representatives of which two are patient representatives. The public interest representatives were appointed following expressions of interest received from members of the HSE National Patients’ Forum. They are equal, voting members.